Original paper
Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice
Abstract
Background null Olaparib (50 mg hard capsules, HC) was the 1st PARPi approved in the EU in 12/2014 as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) ovarian cancer (PSR-OC) who are in response to platinum-based chemotherapy. In addition, film-coated tablets (FT, 100/150 mg) were approved in 05/2018 regardless of BRCA status. Here, we report for the first time data on real-world...
Paper Details
Title
Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice
Published Date
Oct 1, 2019
Journal
Volume
30
Pages
v412 - v412
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History